Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $30.4 million.

  • CorMedix's Free Cash Flow rose 32219.22% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 26499.04%. This contributed to the annual value of -$50.7 million for FY2024, which is 3096.18% down from last year.
  • Latest data reveals that CorMedix reported Free Cash Flow of $30.4 million as of Q3 2025, which was up 32219.22% from $30.0 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Free Cash Flow ranged from a high of $30.4 million in Q3 2025 and a low of -$17.4 million during Q1 2024
  • Moreover, its 5-year median value for Free Cash Flow was -$6.3 million (2021), whereas its average is -$1.8 million.
  • As far as peak fluctuations go, CorMedix's Free Cash Flow crashed by 30837.39% in 2021, and later skyrocketed by 32219.22% in 2025.
  • CorMedix's Free Cash Flow (Quarter) stood at -$6.5 million in 2021, then rose by 3.3% to -$6.3 million in 2022, then tumbled by 65.65% to -$10.4 million in 2023, then soared by 45.96% to -$5.6 million in 2024, then skyrocketed by 639.63% to $30.4 million in 2025.
  • Its Free Cash Flow was $30.4 million in Q3 2025, compared to $30.0 million in Q2 2025 and $19.7 million in Q1 2025.